1557. Population Pharmacokinetics of Suvratoxumab (MEDI4893), an Extended Half-life Staphylococcus aureus Alpha Toxin-Neutralizing Human Monoclonal Antibody, in Healthy Adults and Patients on Mechanical Ventilation in Intensive Care Units

BACKGROUND: Suvratoxumab (suvra), an extended half-life (~80 days), Staphylococcus aureus (SA) alpha toxin-neutralizing IgG monoclonal antibody, is under investigation for prevention of SA pneumonia in patients on mechanical ventilation (MV). We characterized the serum PK of suvra using population p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Open Forum Infect Dis
Main Authors: Pierre, Vadryn, Francois, Bruno, Hernandez-Illas, Martha, Sánchez Garcia, Miguel, Wu, Yuling, Eggimann, Philippe, Laterre, Pierre-Francois, Huberlant, Vincent, Viña, Lucia, Boulain, Thierry, Ruzin, Alexey, Bretonnière, Cédric, Pugin, Jerome, Trenado Álvarez, José, Bellamy, Terramika, Shoemaker, Kathryn, Ali, Omar, Lee, Nancy, Dequin, Pierre-Francois, Jafri, Hasan S, Roskos, Lorin, Colbert, Susan, Khan, Anis
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6809240/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.1421
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados